No abstract available.
Guillain-Barre Syndrome ; Plasmapheresis*

No abstract available.
Plasmapheresis* ; Postpartum Period* ; Pregnancy*

No abstract available.
Hepatitis* ; Immunoglobulins* ; Plasmapheresis*

No abstract available.
Guillain-Barre Syndrome* ; Plasmapheresis*

It is known that in myasthenia gravis(MG) the plasmapheresis therapy removes the acetylcholine receptor (AChR) antibodies and other toxins in the serum to cause clinical improvement temporarily. To know the effects of plasmapheresis on AChR antibody and clinical courses the authors checked serially the AChR antibody titers and clinical stages in myasthenia gravis. The plasmapheresis were performed for the therapeutic purposes in seven and elective purposes in three MG subjects. After two, three or four cycles of plasmapheresis, the myasthenic symptoms have dramatically improved in all subjects. However the AChR antibody titers decreased in only four out of ten and the decremental ratio in each case uas rather smaller than being expected. Thus the effects of plasmapheresis could not be explained solely by the decreasing phenomena of AChR antibody titers in MG subjects. Therefore the authors assumed that the clinical severities of MG could be correlated with other types of AChR antibodies that are not checked by the routine @-bungarotoxin binding technique, or the AChR antibodies are secondarily produced in large amount by the mechanism of rebound enhancing activity.
Acetylcholine* ; Antibodies ; Myasthenia Gravis* ; Plasmapheresis*

The present study was designed to evaluate a beneficial effect of plasmapheresis on Guillain-Barre syndrome comparing wth the combined therapy(plasmapheresis and steroid and/or gamma globulin). Exchange fluid used for plasmapheresis was fresh frozen plasma and the amount of exchanged plasma was 40-50ml/kg in each exchange for 3 to 5 times. Plasmapheresis had been of benefit on Guillain-Barre syndrome. Without serious adverse effect. But there was no difference between the effect of plasmapheresis and the combined therapy.
Guillain-Barre Syndrome* ; Plasma ; Plasmapheresis*

No abstract available.
Plasmapheresis* ; Prednisolone* ; Purpura, Thrombotic Thrombocytopenic*

Immune complexes are found in the circulation of 30%-75% of patients with urticarial vasculitis and much evidence supports the role of these immune complexes in the pathogenesis of urticarial vasculitis. Plasmapheresis is effective for removing these immune complexes; however, there are few reports on the use of plasmapheresis in the treatment of urticarial vasculitis. We describe a case of "refractory" urticarial vasculitis in which the symptoms improved after plasmapheresis treatment. We suggest that plasmapheresis be considered as an option in patients with severe or treatment-resistant urticarial vasculitis.
Antigen-Antibody Complex ; Humans ; Plasmapheresis ; Vasculitis

Plasmapheresis is an emerging treatment for intravenous steroid-resistant neuromyelitis optica (NMO). We present the case of a 16-year-old girl who suffered from intravenous steroid-resistant NMO and whose neurological status improved markedly after treatment with plasmapheresis. This is the first report on the effectiveness of plasmapheresis in NMO in Korea. kwoo@plaza.snu.ac.kr
Adolescent ; Humans ; Korea ; Neuromyelitis Optica ; Plasmapheresis

No abstract available.
Child* ; Guillain-Barre Syndrome* ; Humans ; Plasmapheresis*